<DOC>
	<DOCNO>NCT02262130</DOCNO>
	<brief_summary>Solar urticaria rare disease , usual favourable outcome photoprotection anti H1 histamine . Nevertheless , case severe refractory usual treatment , lead large impact quality life . New treatment option warrant . The investigator aim test efficacy safety omalizumab , anti-IgE antibody recently approve chronic spontaneous urticaria , set .</brief_summary>
	<brief_title>Omalizumab Severe Refractory Solar Urticaria</brief_title>
	<detailed_description>This open-labelled multicentric phase II study test efficacy safety omalizumab 300 mg ( W0 , W4 W8 ) patient affect severe refractory solar urticaria .</detailed_description>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Age &gt; equal 18 year , Appearance wheal within 15 min sun exposure last &lt; 2 hr shade , Wheals reproducible phototesting : appearance exposure UVB , UVA visible light le 30 min exposure last &lt; 2 hr , Severity criterion : Very large effect quality life , Dermatology Life Quality Index ( DLQI ) &gt; 10 , At least 1 follow : involvement face , per annual eruption , extension wheal nonphotoexposed skin , SU trigger artificial light , SU flare accompany bronchospasm syncope . Refractory criterion : Resistance photoprotection sunscreen sun protection factor â‰¥ 50 , Resistance administration association 2 different antihistamine 3 month photodesensitization . Contra indication omalizumab Previous treatment omalizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Omalizumab</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>